Immune checkpoint inhibitors have shown significant therapeutic responses against tumors
containing increased mutation-associated neoantigen load. We have examined the evolving …

As tumors grow, they acquire mutations, some of which create neoantigens that influence
the response of patients to immune checkpoint inhibitors. We explored the impact of …

The treatment landscape for patients with advanced non-small cell lung cancer has evolved
greatly with the advent of immune checkpoint inhibitors. However, many patients do not …

Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …

Despite progress in immunotherapy, identifying patients that respond has remained a
challenge. Through analysis of whole-exome and targeted sequence data from 5,449 …

The evolutionary dynamics of tumor‐associated neoantigens carry information about drug
sensitivity and resistance to the immune checkpoint blockade (ICB). However, the spectrum …

Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial …

Simple Summary Immuno-oncology has redefined the treatment of lung cancer, with the
ultimate goal being the reactivation of the anti-tumor immune response. This has led to the …

Immunotherapy has prompted a paradigm shift in advanced non-small cell lung cancer
(NSCLC) treatment, by demonstrating superior efficacy to chemotherapy alone both in …

Therapies targeting immune checkpoints have recently shown encouraging activity in
patients with heavily pretreated advanced non–small cell lung cancer (NSCLC) …